Midodrine

Administration
  • Type: Vasopressors, alpha-1 agonist
  • Dosage Forms:
  • Routes of Administration: PO
  • Common Trade Names: ProAmatine, Orvaten

Adult Dosing
  • 2.5-10mg PO q8h

Pediatric Dosing

Safety/efficacy not established

Special Populations

Pregnancy Rating
  • Category C

Lactation risk
  • Unknown if excreted in breastmilk

Renal Dosing
  • Adult: 2.5mg PO q8h, increase as tolerated

Hepatic Dosing
  • Adult: Use caution

Contraindications
  • Allergy to class/drug
  • Severe heart disease
  • Supine hypertension
  • Acute renal disease, urinary retention
  • Pheochromocytoma
  • Thyrotoxicosis
  • Caution with:
    • Concomitant beta-blockers or digoxin (reflex bradycardia)
    • Concomitant use of drugs that increase BP (e.g. phenylephrine, levothyroxine, pseudoephedrine)
    • Concomitant MAOIs or linezolid
    • DM
    • Renal or hepatic impairment
    • Vision problems

Adverse Reactions

Serious
  • Bradycardia
  • Raised ICP

Common
  • Paresthesias
  • Piloerection, pruritus, rash, erythema multiforme, flushing
  • Hypertension
  • Urinary retention or urgency
  • Abdominal pain, nausea, xerostomia
  • Chills
  • Anxiety, insomnia, somnolence, weakness
  • Confusion, dizziness
  • Headache
  • Hyperesthesia

Pharmacology
  • Half-life: 3-4h
  • Metabolism: Enzymatic hydrolysis in systemic circulation
  • Excretion: Renal

Mechanism of Action
  • Selective alpha-1 adrenergic agonist

Comments


See Also

References
    This article is issued from Wikem. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.